Press "Enter" to skip to content

FDA approves Celltrion’s biosimilar to Roche’s Herceptin

The treatment, which generated sales of about $7.18 billion in 2017, has been a main contributor to Roche’s profits and is one of the world’s most successful antibody drugs.

Original source:

Also Read:   'Enemy of mankind': Coronavirus deaths top SARS as China returns to work